A Liquid Formulation Of Long-Acting Insulin And Insulinotropic Peptide

Patent No. EP2877201 (titled "A Liquid Formulation Of Long-Acting Insulin And Insulinotropic Peptide") was filed by Hanmi Pharm on Jul 25, 2013. The application was issued on Jun 5, 2019.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
JAMES POOLEMar 5, 2020MARSHALL

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2877201

HANMI PHARM
Application Number
EP13822545A
Filing Date
Jul 25, 2013
Status
Granted And Under Opposition
May 3, 2019
Publication Date
Jun 5, 2019